Cellect Biotechnology Reports Second Quarter 2019 Financial and Operating Results

Tuesday, August 13, 2019 General News
Email Print This Page Comment bookmark
Font : A-A+

Recent Clinical Achievements Demonstrate Continued Momentum in the U.S. and Israel

Cellect Biotechnology Ltd

Consolidated Cash Flow Data

Convenience

translation

Six months

ended

Six months ended

Three months ended

June 30,

June 30,

June 30,

2019

2019

2018

2019

2018

Unaudited

Unaudited

U.S. dollars

NIS

(In thousands)

Cash flows from operating activities:

Total comprehensive loss

(1,660)

(5,919)

(9,564)

(816)

(5,989)

Adjustments to reconcile net loss to net      cash used in operating activities:

Net financing expenses

229

815

(837)

443

(314)

Loss (gain) from revaluation of financial      assets presented at fair value through      profit and loss

2

6

(148)

2

(148)

Depreciation

54

192

215

94

110

Changes in fair value of traded and not      traded warrants

(2,368)

(8,442)

(1,888)

(5,895)

608

Share-based payment

148

529

2,184

744

937

Decrease (increase) in other receivables

40

145

(87)

75

(150)

Increase (decrease) in other payables

(201)

(715)

(1,115)

(730)

(204)

Decrease in right-of-use assets

89

314

-

200

-

Interest received during the period

(13)

(46)

(15)

(46)

(15)

Net cash used in operating activities

(3,680)

(13,121)

(11,255)

(5,929)

(5,165)

Cash flows from investing activities:

Short term deposits, net

-

-

(3,503)

-

(3,503)

Restricted deposit, net

-

-

(28)

-

135

Sales of marketable securities measured at      fair value through profit and loss

-

-

8,498

-

3,998

Purchase of property, plant and equipment

(34)

(120)

(228)

-

(88)

Net cash provided by investing activities

(34)

(120)

4,739

-

542

Cash flows from financing activities:

Exercise of warrants and stock options into      shares

-

-

399

-

-

Leases liabilities

(77)

(278)

-

(178)

-

Issue of share capital and warrants, net of      issue costs

6,653

23,723

12,360

(1,114)

(5)

Net cash provided (used) by financing      activities

6,576

23,445

12,759

(1,292)

(5)

Exchange differences on balances of cash      and cash equivalents

(216)

(769)

852

(397)

329

Increase (decrease) in cash and cash      equivalents

2,646

9,435

7,095

(7,618)

(4,299)

Balance of cash and cash equivalents at the      beginning of the period

4,994

17,809

13,734

34,862

25,128

Balance of cash and cash equivalents at      the end of the period

7,640

27,244

20,829

27,244

20,829



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store